The European stocks bulls must be in Britain
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com.
THE EUROPEAN STOCKS BULLS MUST BE IN BRITAIN
European shares are set to start the week down slightly, with STOXX 50 futures STXEc1 off around 0.25% and Dax FDXc1 and CAC40 FCEc1 futures both trading lower too. British markets are closed for a bank holiday.
A down day is probably due. The broad STOXX 600 posted daily gains for all but one trading session in the past two weeks as shares around the world walked back their losses from early August's turmoil, though the STOXX 50 blue chips didn't quite manage such a milestone, a sign some rotation is taking place.
Monday's macro economic picture is still the one painted by central bankers at the Jackson Hole symposium. Most importantly, Fed chair Jerome Powell on Friday endorsed an imminent start to interest rate cuts, declaring further job market cooling would be unwelcome.
That boosted shares U.S. and European shares on Friday, and the MSCI world index is back at record highs. .MIWD00000PUS
European policy makers were a bit more cautious. The European Central Bank is making "good progress" in cutting inflation back to its 2% target but success is not yet assured, so restrictive monetary policy is still needed, ECB chief economist Philip Lane said on Saturday.
Bank of England Governor Andrew Bailey said it was still too soon to be sure inflation was beaten.
Of course, both the BoE and ECB are speaking from a slightly different position, having already started cutting interest rates.
There's a couple of bits of company news out there.
Nestle NESN.S intends to keep its Health Science unit, Chairman Paul Bulcke said in a newspaper interview published on Sunday. The unit was among those that analysts said could be sold over the medium term, as they try to get a grip on the implications of the food giant replacing its CEO Mark Schneider with company veteran Laurent Freixe.
UCB UCB.BR, a Belgian biopharmaceutical firm, said on Monday that it will sell its Chinese neurology and allergy business for $680 million, and Swiss solar panel maker Meyer Burger MBTN.S said on Monday it was suspending plans for a plant in Colorado.
MONDAY'S EARLIER LIVE MARKETS POSTS
MARKETS REASSURED BY THE POWELL PUTCLICK HERE
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
